Kurs
+0,07%
Kalender
| Est. tid* | ||
| 2025-04-29 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-11 | - | Årsstämma |
| 2025-02-20 | - | X-dag halvårsutdelning AZN 167.999995 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-08 | - | X-dag halvårsutdelning AZN 77.600002 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-11 | - | Årsstämma |
| 2024-02-22 | - | X-dag halvårsutdelning AZN 155.999994 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-10 | - | X-dag halvårsutdelning AZN 71.799999 |
| 2023-07-28 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | X-dag halvårsutdelning AZN 162.800002 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | X-dag halvårsutdelning AZN 76.4 |
| 2022-07-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | X-dag halvårsutdelning AZN 145.299995 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | X-dag halvårsutdelning AZN 64.8 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Årsstämma |
| 2021-04-30 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | X-dag halvårsutdelning AZN 137.399995 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | X-dag halvårsutdelning AZN 69.599998 |
| 2020-07-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | X-dag halvårsutdelning AZN 146.399999 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-08 | - | X-dag halvårsutdelning AZN 71.899998 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | Årsstämma |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | X-dag halvårsutdelning AZN 146.800005 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | - | X-dag halvårsutdelning AZN 68.400002 |
| 2018-07-26 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | X-dag halvårsutdelning AZN 133.599997 |
| 2018-02-02 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | X-dag halvårsutdelning AZN 68.900001 |
| 2017-07-27 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | X-dag halvårsutdelning AZN 150.199997 |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | - | X-dag halvårsutdelning AZN 68.699998 |
| 2016-07-28 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Årsstämma |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | X-dag halvårsutdelning AZN 145.555556 |
| 2016-02-04 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | X-dag halvårsutdelning AZN 63.88889 |
| 2015-07-30 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | Årsstämma |
| 2015-04-24 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | X-dag halvårsutdelning AZN 138.888896 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | X-dag halvårsutdelning AZN 59 |
| 2014-07-31 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-24 | - | Årsstämma |
| 2014-04-24 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-19 | - | X-dag halvårsutdelning AZN 129.777777 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | - | X-dag halvårsutdelning AZN 65.777779 |
| 2013-08-01 | - | Analytiker möte 2013 |
| 2013-08-01 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | - | Årsstämma |
| 2013-04-25 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-13 | - | X-dag halvårsutdelning AZN 133.888888 |
| 2013-01-31 | - | Bokslutskommuniké 2012 |
| 2012-10-25 | - | Analytiker möte 2012 |
| 2012-10-25 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-08 | - | X-dag halvårsutdelning AZN 64.555556 |
| 2012-07-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-26 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-15 | - | X-dag halvårsutdelning AZN 137.333333 |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-03 | - | X-dag halvårsutdelning AZN 57.666665 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Årsstämma |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-02 | - | X-dag halvårsutdelning AZN 129.666662 |
| 2011-01-27 | - | Bokslutskommuniké 2010 |
| 2010-10-28 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-04 | - | X-dag halvårsutdelning AZN 49.888888 |
| 2010-07-29 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-03 | - | X-dag halvårsutdelning AZN 117.111111 |
| 2010-01-28 | - | Bokslutskommuniké 2009 |
| 2009-10-29 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-05 | - | X-dag halvårsutdelning AZN 40 |
| 2009-07-30 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | - | Årsstämma |
| 2009-04-30 | - | Kvartalsrapport 2009-Q1 |
| 2009-02-04 | - | X-dag halvårsutdelning AZN 116.444444 |
| 2008-08-06 | - | X-dag halvårsutdelning AZN 30.888888 |
| 2008-02-06 | - | X-dag halvårsutdelning AZN 75.2222222 |
| 2007-08-08 | - | X-dag halvårsutdelning AZN 28.111111 |
| 2007-02-07 | - | X-dag halvårsutdelning AZN 70 |
| 2006-08-09 | - | X-dag halvårsutdelning AZN 32.562658 |
Beskrivning
| Land | Storbritannien |
|---|---|
| Lista | FTSE 100 |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators. The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.
AstraZeneca and the University of Oxford, as the trial sponsor, cannot disclose further medical information. All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards.
AstraZeneca is committed to the safety of trial participants and the highest standards of conduct in clinical trials. The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic.
AZD1222
AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).